Improved antitumor activity through a tyramidyl maslinic acid derivative. Design and validation as drug-loaded

Cristina Luque1, María de la Cabeza Fernández2, David Fuentes-Rios3

  • 1Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, Granada 18100, Spain; Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, Granada 18071, Spain; Biosanitary Institute of Granada (ibs. GRANADA), Granada 18014, Spain.